Korea's Celltrion Banks On Increasing Profits Resulting From New Focus On Biosimilars
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Biopharmaceutical firm Celltrion posted a record performance in the most recent quarter due to the company's shift in focus from contract manufacturing to producing biosimilars
You may also be interested in...
Jordanian FDA Drug Director Laila Jarrar On Collaborations With Korean Regulators To Spur Biologics Growth - An Interview With PharmAsia News
The fast-growing pharmaceutical market in the Middle East has seen an increasing demand for regulators to step up to new challenges such as biologics and biosimilars, and to answer the call they are enhancing collaborations with leading health authorities around the world.
Jordanian FDA Drug Director Laila Jarrar On Collaborations With Korean Regulators To Spur Biologics Growth - An Interview With PharmAsia News
The fast-growing pharmaceutical market in the Middle East has seen an increasing demand for regulators to step up to new challenges such as biologics and biosimilars, and to answer the call they are enhancing collaborations with leading health authorities around the world.
Korea's Celltrion and Sanofi-Aventis In Line With 2008 Strategic Alliance For Monoclonal Antibodies
SEOUL - Despite Celltrion's claims that it is shifting away from its contract manufacturing business to focus on biosimilars, the company revealed an ongoing deal with Sanofi-Aventis for clinical materials and process development for monoclonal antibody therapeutics and announced the near completion of its CMO plant